Category: 227940-70-7

On June 24, 1999, Strandlund, Gert; Alstermark, Christer; Bjore, Annika; Bjorsne, Magnus; Frantsi, Marianne; Halvarsson, Torbjorn; Hoffmann, Kurt-Jurgen; Lindstedt, Eva-Lotte; Polla, Magnus published a patent.HPLC of Formula: 227940-70-7 The title of the patent was Preparation of 3,7-diazabicyclo[3.3.1]nonane-3-carboxylates as antiarrhythmic agents. And the patent contained the following:

Title compounds [I; R1,R2 = H or alkyl; R1R2 = OCH2CH2O, (CH2)4-5; R3 = CCR10R11AR; A = bond, alkylene, (CH2)nZ, CONR20, etc.; B = bond, alkylene, NR23(CH2)r, O(CH2)r; R = (un)substituted Ph; R4 = COXR9; R9 = alkyl, (un)substituted phenyl(alkyl), -naphthyl; R10 = H or OH; R11,R20,R23 = H or alkyl; X = O or S; Z = NR20, SO0-2, O; n,r = 0-4] were prepared Thus, 4-(NC)C6H4OH was condensed with epichlorohydrin and the product aminated by I (R1 = R2 = H, R4 = CO2CMe3)(II; R3 = H)(preparation given) to give II [R3 = CH2CH(OH)CH2OC6H4(CN)-4]. Data for biol. activity of I were given. The experimental process involved the reaction of tert-Butyl 7-benzyl-9-oxo-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate(cas: 227940-70-7).HPLC of Formula: 227940-70-7

The Article related to diazabicyclononanecarboxylate preparation antiarrhythmic agent, Heterocyclic Compounds (More Than One Hetero Atom): Eight- and Higher-Membered Rings and other aspects.HPLC of Formula: 227940-70-7

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On May 2, 2006, Baldwin, John J.; Tran, Vinh D. published a patent.HPLC of Formula: 227940-70-7 The title of the patent was Preparation of a diazabicyclononane scaffold which is useful in for combinatorial synthesis. And the patent contained the following:

Diazabicyclononanes [I; A = CHNHR1; R1 = H, residue of a solid substrate; R2 = H, amino-protecting group; with the proviso that no more than one of R1, R2 and R3 is H; e.g., II] and their synthesis are described and are useful as scaffolds for constructing combinatorial libraries. The experimental process involved the reaction of tert-Butyl 7-benzyl-9-oxo-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate(cas: 227940-70-7).HPLC of Formula: 227940-70-7

The Article related to diazabicyclononane preparation scaffold combinatorial synthesis, Heterocyclic Compounds (More Than One Hetero Atom): Eight- and Higher-Membered Rings and other aspects.HPLC of Formula: 227940-70-7

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On April 11, 2013, Boss, Christoph; Brotschi, Christine; Heidmann, Bibia; Sifferlen, Thierry; Williams, Jodi T. published a patent.Reference of tert-Butyl 7-benzyl-9-oxo-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate The title of the patent was Preparation of diazabicyclononane derivatives for use as orexin receptor antagonists. And the patent contained the following:

Title compounds I [A = (un)substituted Ph or heteroaryl; B = (un)substituted heteroaryl; X = CH2 or O], and their pharmaceutically acceptable salts, are prepared and disclosed as orexin receptor antagonists. Thus, e.g., II was prepared by a multistep procedure (preparation given). I were evaluated in OX1 receptor assays, e.g., II demonstrated an IC50 value of 8 nM. The experimental process involved the reaction of tert-Butyl 7-benzyl-9-oxo-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate(cas: 227940-70-7).Reference of tert-Butyl 7-benzyl-9-oxo-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate

The Article related to diazabicyclononane derivative preparation orexin receptor antagonist, Heterocyclic Compounds (More Than One Hetero Atom): Eight- and Higher-Membered Rings and other aspects.Reference of tert-Butyl 7-benzyl-9-oxo-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On June 6, 2012, Han, Haitao; Pan, Jianfeng; Jiang, Zhigan; Hu, Tao; Ma, Rujian; Chen, Shuhui published a patent.Application In Synthesis of tert-Butyl 7-benzyl-9-oxo-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate The title of the patent was A process for preparing diazabicyclo[3.3.1]nonane derivatives. And the patent contained the following:

The invention relates to a process for the preparation of diazabicyclo[3.3.1]nonane derivative I, useful as intermediate for manufacturing antiarrhythmic drugs. For instance, the compound I was prepared by heterocyclization of N-Boc-4-oxopiperidine with formaldehyde and benzylamine followed by addition to 1-[(isocyanomethyl)sulfonyl]-4-methyl-benzene, hydrolysis, protection with (Boc)2O, reduction, and protection with CbzCl. The experimental process involved the reaction of tert-Butyl 7-benzyl-9-oxo-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate(cas: 227940-70-7).Application In Synthesis of tert-Butyl 7-benzyl-9-oxo-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate

The Article related to diazabicyclononane derivative preparation antiarrhythmic intermediate, Heterocyclic Compounds (More Than One Hetero Atom): Eight- and Higher-Membered Rings and other aspects.Application In Synthesis of tert-Butyl 7-benzyl-9-oxo-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On October 7, 2010, Neelamkavil, Santhosh Francis; Neustadt, Bernard R.; Stamford, Andrew; Xia, Yan; Harris, Joel M.; Boyle, Craig D.; Chackalamannil, Samuel; Biswas, Dipshikha; Liu, Hong; Hao, Jinsong; Lankin, Claire M.; Shah, Unmesh G. published a patent.Electric Literature of 227940-70-7 The title of the patent was Bridged bicyclic heterocycle derivatives as GPCR modulators and their preparation and use in the treatment of GPCR-related disorders. And the patent contained the following:

The invention relates to bridged bicyclic heterocycle derivatives of formula I, compositions comprising compounds of formula I, and methods of using compounds of formula I for treating or preventing disorders related to the activity of a GPCR in a patient. Compounds of formula I wherein A is (un)substituted pyridyl and pyrimidinyl; B is (un)substituted Ph and (un)substituted heteroaryl; W is a bond, CO, CONH, CO2, COS, and SO2; X is O, oxyalkylene and NH; Y is O and NH; Z is a bond, CO, (un)substituted methylene, O, SO2, and NH and derivatives; R3 is alkyl, alkylenearyl, cycloalkyl, alkylenecycloalkyl, etc.; D, E, F, Q, and U are independently absent and CH2; and their pharmaceutically acceptable salts, solvates, esters, prodrugs and stereoisomers, are claimed. Example compound II was prepared by a multistep procedure (procedure given). All the invention compounds were evaluated for their GPCR modulatory activity. From the assay, it was determined that the invention compounds exhibited EC50 values in the range from about 3 nM to about 200 nM. The experimental process involved the reaction of tert-Butyl 7-benzyl-9-oxo-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate(cas: 227940-70-7).Electric Literature of 227940-70-7

The Article related to bridge bicyclic heterocycle derivative preparation gpcr modulator treatment disorder, Heterocyclic Compounds (More Than One Hetero Atom): Eight- and Higher-Membered Rings and other aspects.Electric Literature of 227940-70-7

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On December 21, 2000, Bjore, Annika; Bjorsne, Magnus; Halvarsson, Torbjorn; Hoffmann, Kurt-jurgen; Samuelsson, Bertil; Strandlund, Gert published a patent.Electric Literature of 227940-70-7 The title of the patent was Preparation of new bispidines useful in the treatment of cardiac arrhythmias. And the patent contained the following:

Bispidines, such as I [R1 = alkyl, arylalkyl, etc.; R2, R3 = H, OH, alkyl, etc.; R2R3 = O; R4, R5a, R5b = H, alkyl; R6 = OH, CN, NO2, NH2, halogen, etc.; X = O, S; A, B = bond, linking group, such as alkylene, etc.; D = H, OH, alkyl, aminoalkyl, etc.], were prepared for pharmaceutical use in the treatment of cardiac arrhythmias, in particular atrial and ventricular arrhythmias. Thus, bispidine II was prepared in multistep synthetic sequence starting from Et 4-oxo-1-piperidinecarboxylate, epichlorohydrin, and 4-cyanophenol. The prepared bispidines were tested for primary electrophysiol. effects in anesthetized guinea pigs. The experimental process involved the reaction of tert-Butyl 7-benzyl-9-oxo-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate(cas: 227940-70-7).Electric Literature of 227940-70-7

The Article related to bispidine preparation cardiac arrhythmia treatment, antiarrhythmic bispidine preparation, Heterocyclic Compounds (More Than One Hetero Atom): Eight- and Higher-Membered Rings and other aspects.Electric Literature of 227940-70-7

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On December 21, 2000, Alstermark, Christer; Andersson, Kjell; Bjore, Annika; Bjorsne, Magnus; Lindstedt, Alstermark Eva-Lotte; Nilsson, Goran; Polla, Magnus; Strandlund, Gert; Ortengren, Ylva published a patent.COA of Formula: C19H26N2O3 The title of the patent was Preparation of new bispidines useful in the treatment of cardiac arrhythmias. And the patent contained the following:

Bispidines, such as I [R3 = H, alkyl; R4 = H, alkyl, alkoxy; NR3R4 = heterocyclyl; R5 = H, halogen, alkyl, alkoxy, acyloxy, alkylsulfonyloxy, carbamoyl, etc.; R6 = H, alkyl; R5R6 = O; R7 = alkyl, aryl, heterocyclyl; A, B = bond, linking group, such as alkylene, etc.], were prepared for pharmaceutical use in the treatment of cardiac arrhythmias, in particular atrial and ventricular arrhythmias. Thus, bispidine II was prepared with 51% yield by amidation of (S)-4-[3-(3,7-diazabicyclo[3.3.1]non-3-yl)-2-hydroxypropoxy]benzonitrile with Et isocyanate. The prepared bispidines were tested for primary electrophysiol. effects in anesthetized guinea pigs. The experimental process involved the reaction of tert-Butyl 7-benzyl-9-oxo-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate(cas: 227940-70-7).COA of Formula: C19H26N2O3

The Article related to bispidine preparation cardiac arrhythmia treatment, antiarrhythmic bispidine preparation, Heterocyclic Compounds (More Than One Hetero Atom): Eight- and Higher-Membered Rings and other aspects.COA of Formula: C19H26N2O3

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On March 26, 2020, Follows, Bruce; Kayser-Bricker, Katherine J.; Talbot, Adam Charles; Mente, Scot; Shelekhin, Tatiana; Ericsson, Anna published a patent.Product Details of 227940-70-7 The title of the patent was Preparation of pyrrolo-pyrrolyl alkanones as ubiquitin specific peptidase 9X inhibitors useful for treatment of cancer. And the patent contained the following:

The disclosure provides novel chem. compounds of formula I useful as inhibitors of ubiquitin specific peptidase 9X (USP9X) useful for treatment of diseases and disorders associated with modulation of USP9X such as cancer. Compounds of formula I [wherein X = CR5R6, CR5, NR5, or N; dashed bonds are independently single or double bonds; Y1, Y2, and Y3 independently = N or CRa; Ra independently = H, halo, or CN; Ring A = (un)substituted 5- to 6-membered aryl, (un)substituted 5- to 6-membered heteroaryl, (un)substituted 5- to 7-membered heterocyclyl, etc.; Z1 = O, S, or NR; Z2 = O or NR; W = CH2 and derivative, O, S, etc.; m = 0 or 1; R1 and R2 independently = H, halo, C1-6alkyl, etc.; R3, R4, R5, R6, R7, R8, R9, and R10 independently = H, (un)substituted C1-6alkyl, (un)substituted C3-8cycloalkyl, etc.; each R independently = H, OH, NH2, O(C1-6alkyl), etc.; B = monocyclic or bicyclic 3- to 14-membered ring] or pharmaceutically acceptable salts thereof, are claimed and exemplified. Example compounds (R)-II and (S)-II were prepared from a multistep preparation culminating in chiral separation (preparation given). Exemplified I were evaluated for USP9X inhibitory activity from which both (R)- and (S)-II isomers demonstrated IC50 between ≤ 0.2μM and ≥ 0.05μM. The experimental process involved the reaction of tert-Butyl 7-benzyl-9-oxo-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate(cas: 227940-70-7).Product Details of 227940-70-7

The Article related to pyrrolopyrrolyl alkanone preparation ubiquitin specific peptidase9x inhibitor cancer, Heterocyclic Compounds (More Than One Hetero Atom): Other 5-Membered Rings, Two Or More Hetero Atoms and other aspects.Product Details of 227940-70-7

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On November 6, 2020, Li, Gonglin; Liu, Mohuizi; Zou, Sijia; Feng, Xiaoming; Lin, Lili published an article.Formula: C19H26N2O3 The title of the article was A Bispidine-Based Chiral Amine Catalyst for Asymmetric Mannich Reaction of Ketones with Isatin Ketimines. And the article contained the following:

A unique chiral amine organocatalyst with a bispidine structure was found to be efficient for the diastereo- and enantioselective Mannich reaction of isatin ketimines with ketones. A series of 3-substituted 3-amino-2-oxindoles, e.g., I, bearing vicinal tertiary and quaternary chiral stereogenic centers were obtained in excellent yields with excellent dr and ee values. The gram-scale synthesis and transformation of the product showed the practicability of this methodol. In addition, a possible transition state model was proposed to explain the origin of the stereoselectivity. The experimental process involved the reaction of tert-Butyl 7-benzyl-9-oxo-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate(cas: 227940-70-7).Formula: C19H26N2O3

The Article related to isatin ketimine ketone enantioselective diastereoselective bispidine chiral catalyst mannich, amino oxindole stereoselective preparation, Heterocyclic Compounds (One Hetero Atom): Indoles, Indolizines, Carbazoles, and Other Arenopyrroles and other aspects.Formula: C19H26N2O3

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On November 12, 2009, Chesworth, Richard; Shapiro, Gideon; Chantigny, Yves; Mancuso, John; Deziel, Robert published a patent.Safety of tert-Butyl 7-benzyl-9-oxo-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate The title of the patent was Preparation of azabicyclo[2.2.1]heptan-2-yl compounds as HDAC inhibitors and therapeutic uses thereof. And the patent contained the following:

Inhibitors of histone deacetylase of general formula I (wherein R4 is H, C1-C6alkyl, C2-C6 alkenyl, etc.; each A is N, N-oxide, -CH=, and -C(R4)=; Z is -N(R1)OR2 or H; L is a covalent bond or -C0-C3alkyl-N(OR2)-; G2 is C or N; U2 is a covalent bond, -C1-C6alkyl, C3-C6cycloalkyl, etc.; R200, R201, R202 and R203 are independently H, C1-C6alkyl, aryl, etc.; B3 is H, aryl, heteroaryl, etc.; R1 and R2 are independently H, C1-C6alkyl, aryl, etc.) are described together with methods for treating various disorders with such compounds Such disorders include Huntington’s disease, dentatorubralpallidoluysian atrophy, spinal and bulbar muscular atrophy, and spinocerebellar ataxias. Synthetic procedures for preparing I are exemplified, but no biol. data is given. Example compound II was prepared in a 5-step synthesis that involved reaction of intermediate (1S,4S)-2-benzhydryl-2,5-diazabicyclo[2.2.1]heptane 2HCl with Et 2-(methylsulfonyl)pyrimidine-5-carboxylate and reaction of the intermediate formed with hydroxylamine. The experimental process involved the reaction of tert-Butyl 7-benzyl-9-oxo-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate(cas: 227940-70-7).Safety of tert-Butyl 7-benzyl-9-oxo-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate

The Article related to azabicycloheptanyl compound preparation hdac inhibitor nervous system disease treatment, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazines and Quinoxalines (Including Piperazines) and other aspects.Safety of tert-Butyl 7-benzyl-9-oxo-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics